Guardant Health Launches New Guardant360 TissueNext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer
Portfolio Pulse from Benzinga Newsdesk
Guardant Health has launched an upgraded version of its Guardant360 TissueNext test, which now includes 498 biomarkers to help identify more treatment options for patients with advanced cancer. The test is covered by Medicare and features operational improvements for faster results.
June 04, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health has launched an upgraded version of its Guardant360 TissueNext test, expanding the number of biomarkers to 498 and improving operational workflow for faster results. The test is also covered by Medicare.
The launch of the upgraded Guardant360 TissueNext test is likely to positively impact Guardant Health's stock price in the short term. The expanded biomarker panel and faster turnaround time enhance the test's value proposition, potentially increasing demand. Additionally, Medicare coverage for comprehensive genomic profiling of all advanced solid tumors further supports the test's market adoption.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100